Regenxbio (RGNX) Stock Plummets 25% as FDA Halts Gene Therapy Trial
Regenxbio's stock fell 25% to $8.05 after the FDA placed a clinical hold on its gene therapy candidate RGX-121 due to spinal nodules in five trial participants. The company halted near-term BLA resubmission plans for RGX-121 but will file a BLA for its Duchenne treatment this quarter and expects wet AMD trial results in Q4. According to the company, the nodules are likely benign, but the FDA required further review.
How this was made
The 30-second read
Why it matters
The hold halts near‑term BLA resubmission, prompting a sharp sell‑off and raising questions about the pipeline's risk profile.
Market read
The FDA action triggers a 25% price drop, likely influencing peer biotech stocks and sector sentiment.
What to watch
The company's Duchenne and wet‑AMD programs are unaffected and could provide near‑term catalysts.
Background
Regenxbio announced a clinical hold on its Hunter syndrome gene therapy after MRI scans revealed benign nodules in five participants.
Ticker impact
FDA placed a clinical hold on Regenxbio's gene therapy RGX-121, causing the stock to drop 25% in Monday trading.
Further downside pressure likely until clarification or trial data are released.
A 25% intraday move on a fresh FDA action signals strong short-term sell pressure.
Market effects
Gene‑therapy and broader biotech stocks may see heightened scrutiny after the hold.
US biotech sector faces short‑term volatility.
International investors in rare‑disease therapeutics may reassess exposure.
Counterpoint
If the FDA hold is limited to imaging findings, the long‑term value of the platform could remain intact.
Key entities
- companyRegenxbio Inc.
Biotech firm developing gene‑therapy candidates.
- regulatorFDA
U.S. Food and Drug Administration.
